Cover Image
市場調查報告書

進化的進入市場策略:醫藥品先進市場的藥價設定、償付環境

Evolving Market Access Strategies - Pricing and Reimbursement Landscape in Major Developed Pharmaceutical Markets

出版商 CBR Pharma Insights 商品編碼 351876
出版日期 內容資訊 英文 86 Pages
訂單完成後即時交付
價格
Back to Top
進化的進入市場策略:醫藥品先進市場的藥價設定、償付環境 Evolving Market Access Strategies - Pricing and Reimbursement Landscape in Major Developed Pharmaceutical Markets
出版日期: 2016年01月01日 內容資訊: 英文 86 Pages
簡介

本報告提供進入醫藥品市場的主要課題的相關調查,進入市場的HEOR (Health Economic and Outcomes Research) 的重要角色,醫療技術評估 (HTA) 的優點,償付決策中HTA的重要性擴大,主要國家的藥價設定及償付政策等彙整資料。

摘要整理

簡介

HEOR (Health Economic and Outcomes Research)

  • HEOR的綜合性價值創造計劃
  • 經濟評估的各種類型
  • 成本效益分析概要
  • HEOR的品質調整生存年
  • 醫療經濟學的建模手法

進入市場的醫療技術評估 (HTA)

  • HTA的優點
  • HTA的流程、方面
  • HTA法規當局
  • 案例研究
  • 憑證在特定場合的風險共享的協定

藥價設定、償付

  • 價格決策的因素
  • 新藥的藥價設定

美國的藥價設定政策

  • Affordable Care Act的影響
  • 案例研究

加拿大的藥價設定、償付政策

歐洲的藥價設定、償付政策 (英國、德國、法國、義大利、西班牙)

  • 案例研究
  • 平行貿易

日本的藥價設定、償付政策

臨床試驗與經濟分析

有效的進入市場的藥物核准、銷售的協調

實現最適合的市場進入的課題

要點

目錄
Product Code: GBI070CBR

Summary

GBI Research's latest report, "Evolving Market Access Strategies - Pricing and Reimbursement Landscape in Major Developed Pharmaceutical Markets" assesses developments within the key elements of market access such as Health Economics and Outcome Research (HEOR), Health Technology Assessment (HTA) as well as pricing and reimbursements strategies for pharmaceutical products. This new report also discusses the need to integrate market access strategies earlier into the drug development process, in order to save time and costs related to conducting additional studies to prove the added benefits of a product. Additionally, our new study analyses the role of HTAs in market access and alternatives that could be used in cases where there is limited evidence. Detailed analysis of pricing and reimbursement policies in North America, five key European countries and Japan are also included in this report along with a myriad of relevant case studies. In order to gain optimum market access, companies have to analyze the economic benefit of the treatment, the level of competition and the required reimbursement support.

Scope

Payers continue to play an important role in market access. Products are increasingly being rejected for reimbursement, adversely affecting the market share of these products.

  • What strategies can pharmaceutical companies implement in order to overcome these challenges?
  • HEOR plays a critical part in market access
  • How does HEOR help internal decision making?
  • How can a systemic value development plan (SVDP) optimize HEOR?
  • How do cost-effectiveness analyses play a role in the commercial success of a new product?
  • HTA has gained importance in reimbursement decisions
  • What are the different concepts and general processes involved in HTA?
  • What are the key benefits of HTA?
  • Pricing and reimbursement are the key elements of market access
  • What are the most important factors considered in pricing decisions?
  • What are the pricing and reimbursement policies in the US, Canada, UK, Germany, France, Italy, Spain and Japan?

Key Reasons to Purchase

This report will allow you to -

  • Gain insights into current market access strategies and evolving approaches: This report describes fundamental concepts about market access, its key elements and the evolving landscape in key markets.
  • Understand the role of HEOR in market access and pricing: This report provides insights about role of HEOR in market access and the different economic aspects measured in these studies.
  • Understand HTA and its role in reimbursement: This includes detailed analysis on the benefits of HTA in market access, the various dimensions of HTA as well as case studies that highlight the role of these studies in the potential commercial success of a product.
  • Review the involvement of Risk Sharing Agreements (RSAs) in market access: Includes details about the involvement of a RSA when there is limited evidence available for conducting HTAs as well as the various approaches involved in RSAs
  • Understand pricing of pharmaceutical products in the US: Includes pricing policies in the US along with the impact of the Affordable Care Act (ACA) on pricing decisions. Specific case studies deliver analyses of the current market access landscape in the US.
  • Assess pricing and reimbursement in Europe and Japan: Includes pricing and reimbursement policies in five key European countries and Japan. Specific case studies demonstrate critical market access factors to be considered in these countries.

Table of Contents

Executive Summary

Introduction

Health Economic and Outcomes Research (HEOR)

  • A Systemic Value Development Plan for HEOR
  • Types of Economic Evaluations
  • Overview of Cost-Effectiveness Analysis
  • Quality-Adjusted Life Year in HEOR
  • Pharmacoeconomic Modelling Methods

Health Technology Assessment (HTA) in Market Access

  • Key Benefits of HTA
  • Process and Dimensions of HTA
  • Principle HTA Regulatory Agencies
  • Case Studies
  • Risk Sharing Agreements When Limited Evidence is Available for HTA

Pricing and Reimbursement

  • Factors Affecting Pricing Decision
  • Pricing of a New Drug

Pharmaceutical Pricing Policies in the US

  • Impact Of Affordable Care Act on Market Access
  • Case Studies

Pharmaceutical Pricing and Reimbursement Policies in Canada

Pharmaceutical Pricing and Reimbursement Policies in Europe (UK, Germany, France, Italy and Spain)

  • Case Studies
  • Parallel Trade in Europe

Pharmaceutical Pricing and Reimbursement Policies in Japan

Economic Analysis Alongside Clinical Trials

Harmonization of Drug Approval and Marketing for Effective Market Access

Key Challenges for Achieving Optimum Market Access

Key Takeaways

Back to Top